We sought to measure the characteristics of a quantitative human papillomavirus deoxyribonucleic acid assay and repeated cervical cytologic examination in screening for cervical intraepithelial neoplasia among human immunodeficiency virus-infected women. STUDY DESIGN: Human immunodeficiency virus-infected women with screening CD4 + lymphocyte counts of ≤500 cells/mm 3 (n = 103) were examined by quantitative human papillomavirus deoxyribonucleic acid assay and serial cervical cytologic examination and by colposcopy with biopsy and endocervical curettage during the course of 1 year. RESULTS: Quantitative measures of total human papillomavirus deoxyribonucleic acid and high-risk human papillomavirus deoxyribonucleic acid were strongly associated with any cervical intraepithelial neoplasia (P = .005) and high-grade cervical intraepithelial neoplasia (P = .0006), but they improved the sensitivity and negative predictive value of baseline screening only slightly when combined with cervical cytologic examination. Incident cervical intraepithelial neoplasia occurred frequently (20%) during 1 year of follow-up and was more common among human papillomavirus-infected women. Repeated cytologic examination identified 60% of women with new cervical intraepithelial neoplasia. CONCLUSION: Human immunodeficiency virus-infected women with at least mild immunosuppression have a high incidence of cervical intraepithelial neoplasia, which warrants close follow-up. Those with high baseline human papillomavirus deoxyribonucleic acid levels may be at the highest risk for incident cervical intraepithelial neoplasia. (Am J Obstet Gynecol 2001;184:322-30.) 
Cervical intraepithelial neoplasia (CIN) and cervical carcinoma are more frequent and more refractory to treatment among women infected with human immunodeficiency virus (HIV) than among immunologically healthy women. 1, 2 The effectiveness of routine cervical cytologic examination in screening for such abnormalities has been questioned in several studies. [3] [4] [5] Some authorities have recommended screening with more frequent cervical cytologic examinations, whereas others have recommended screening colposcopy. Assays for human papillomavirus (HPV) deoxyribonucleic acid (DNA) detection have been studied as an adjunct to cervical cytologic examination in certain populations of women but have not been examined as an alternative or complement to cytologic screening among HIV-infected women.
We found that the screening characteristics of cervical cytologic examination and a commercially available HPV DNA assay were comparable among HIV-infected women, with pathologic examination of cervical tissue obtained at colposcopy as the reference standard. Use of the two procedures in parallel did not significantly improve screening at baseline. We also evaluated semiannual Papanicolaou tests for detection of incident and progressive CIN. The odds of CIN were lower by 50% among women with normal follow-up cytologic results. However, we observed a 20% incidence of CIN among HIV-infected women with at least mild to moderate immunosuppression and with normal cytologic and cervical histologic results at baseline. We therefore believe that ongoing close follow-up is prudent.
Material and methods
HIV-infected women ≥18 years old who had CD4 + lymphocyte counts of ≤500/mm 3 at the most recent clinical visit and were receiving primary care in 6 United States cities were recruited. Patients were excluded if they had a history of cervical cancer, a history of cervical dysplasia requiring treatment within the preceding 2 years, or a current bleeding diathesis. Pregnant women were not enrolled, because pregnancy was considered a contraindication to elective colposcopic biopsy and endocervical curettage. The protocol was approved by the institutional review board at each site, and each woman provided written informed consent before study entry.
At the initial study visit each participant underwent an interview and pelvic examination. A specimen from the cervical os was obtained on a polyethylene terephthalate (Dacron) swab for HPV DNA detection. An endocervical specimen was obtained with a Cytobrush Plus Cell Collector (Medscand USA, Hollywood, Fla) for cytologic examination, and colposcopy with endocervical curettage was performed. The colposcopist obtained biopsy specimens of all suspect areas and one normal-appearing area or, in the absence of abnormalities, obtained cervical biopsy specimens at the 2 and 10 o'clock positions.
Follow-up visits, which included an interview, speculum examination, and Papanicolaou test, were scheduled at 6 and 12 months. Colposcopy, endocervical curettage, and biopsy were repeated at the 12-month visit. Women with CIN I had additional visits at months 3 and 9 for Papanicolaou tests and colposcopy, with biopsy as indicated. Women with CIN II or CIN III were referred for treatment.
Cytologic slides, curettage specimens, and biopsy specimens were examined in local laboratories and then reexamined in a masked fashion in batches by a central cytopathologist (Thomas R. Kluzak). Cytologic results were reported according to the 1991 Bethesda System. 6 Colposcopic biopsy and endocervical curettage specimens were classified as no pathologic diagnosis, suspect or inconclusive, inflammation, HPV or condyloma acuminatum, CIN I, CIN II, CIN III, or invasive carcinoma.
Cervical swabs were preserved in prepackaged sample transport medium, shipped to a central repository within 14 days, and frozen at -70°C for as long as 12 months. All swabs from initial visits were analyzed as a single batch in the laboratory of Dr Attila Lörincz at Digene Corporation, Silver Spring, Md. No information regarding cytologic or pathologic results was provided to the HPV testing laboratory until the results had been analyzed and reported.
The Hybrid Capture (Digene Corporation) tube assay for HPV DNA has been previously described. 7 The assay for low-risk HPV (rarely associated with cervical cancer) included probes for types 6, 11, 42, 43, and 44. The assay for high-risk HPV types (associated with most cervical cancers) included probes for types 16, 18, 31, 33, 35, 45 , 51, 52, and 56. Results were expressed as the ratio of relative light units emitted from each specimen to the mean of the light emitted by 3 positive control specimens (RLU/PC ratio). An RLU/PC ratio of ≥1 was rated as a positive result. The RLU/PC ratio is correlated with the amount of target DNA in the patient specimen; thus the RLU/PC ratio provides an estimate of the quantity of target DNA contained in the specimen. For analysis of quantitative HPV DNA results the RLU/PC ratios for the lowrisk and high-risk probe mixtures were summed to provide an estimate of the total HPV DNA in each specimen. The RLU/PC ratio for the high-risk probe mixture was used as an estimate of the quantity of high-risk HPV DNA in each specimen.
Sensitivities, specificities, and positive and negative predictive values of various screening procedures were estimated. We report likelihood ratios, which provide similar information as predictive values but are less influenced by disease prevalence and therefore can be compared across studies and across populations. 8 Receiver operating characteristic curves were used to compare screening characteristics of Papanicolaou tests and HPV DNA assays across a range of values. 8 The Cohen κ for interrater agreement was used to compare results between the local and central cytopathologists. 9 Dichotomous variables were tested for significance with the Fisher exact test, and continuous variables were tested with the Wilcoxon 2-sample test.
Data were analyzed with the SAS statistical software package (SAS Institute, Inc, Cary, NC) with some exceptions. The κ statistic and exact 95% confidence intervals for proportions were calculated with EpiInfo version 6.02 (USD, Incorporated, Stone Mountain, Ga) software, and likelihood ratios with their approximate 95% confidence intervals were calculated with PEPI version 2.0 (USD, Incorporated) software.
All analyses were performed with local cytopathologic results and were repeated with central cytopathologic results.
Results

Patients.
One hundred nine HIV-infected women with screening CD4 + lymphocyte counts <500 cells/mm 3 had a baseline study visit. HPV DNA swabs were missing for 6 women. Analyses of cytologic and biopsy results with and without these 6 women were the same, so for clarity the results for those with complete data are presented. The median age was 33 years (range, 20-56 years). Forty-seven women were white, 37 were African American, 13 were Latina or Hispanic, and 6 were of other racial or ethnic groups. Forty-four women defined sex with a high-risk male partner as the risk factor for acquisition of HIV infection, 38 identified drug injection as the risk factor, 6 had other known risk factors, and 17 women had no specific risk factor as defined by the Centers for Disease Control and Prevention but were heterosexually active. The median number of lifetime sexual partners was 10 (range, 1->1000). Only 6 women had diagnoses of acquired immunodeficiency syndrome-defining illness, and another 35 fulfilled the Centers for Disease Control and Prevention definition of acquired immunodeficiency syndrome because of a CD4 + lymphocyte count of ≤200 cells/mm 3 . The median CD4 + lymphocyte count obtained at the baseline visit was 271 cells/mm 3 (range, 6-562 cells/mm 3 ). According to the standard of care at the time and patient choice, 48 women were receiving antiretroviral therapy with a single nucleoside analog, 25 women were receiving dual nucleoside analog therapy, and 30 women were receiving no antiretroviral agents. Plasma HIV ribonucleic acid testing was not in clinical use. Although none of the participants had previous cervical cancer or had required treatment for cervical dysplasia in the preceding 2 years, 39 had been informed of an abnormal Papanicolaou test result sometime in the past.
Sixty-eight women had HPV infection of the uterine cervix according to the Hybrid Capture tube assay, and 58 were infected with high-risk HPV types. Positive results for low-risk types ranged between 1 and 86 RLU/PC, results for high-risk types ranged between 1 and 320 RLU/PC, and the summed results for total HPV DNA ranged between 1 and 328 RLU/PC. Cytopathologic examination. Epithelial cell abnormalities were diagnosed in 36 of the 101 women with satisfactory baseline Papanicolaou specimens by local cytologists and in 43 of the 100 women with available and satisfactory Papanicolaou specimens by the central cytologist (Table I) . Two specimens were considered unsatisfactory for interpretation; because all participants underwent colposcopy with biopsy and curettage, the unsatisfactory samples were not repeated. The interrater agreement (Cohen κ) between the local and central cytologists for any epithelial cell abnormality was 0.66 (good agreement). All epithelial cell abnormalities were considered abnormal results and indications for colposcopy.
CIN was diagnosed in 29 of 103 women by local pathologists and in 43 of 102 women by the central pathologist (1 woman's biopsy specimen was not available for central review; Table I ). The interrater agreement between local and central interpretations for the diagnosis of any CIN on cervical tissue was 0.43 (fair), and the agreement for high-grade CIN was 0.77 (excellent).
The 2 women with unsatisfactory Papanicolaou specimens on local readings had CIN II or CIN III on biopsy. Local cytologic results were reported as normal or benign cellular change for 10 of the 27 women with locally diagnosed CIN (37%) and 2 of the 12 women with high-grade CIN (17%). The central cytopathologist diagnosed 12 of 34 cases of CIN (35%) among women whose central Papanicolaou test interpretations were normal or benign cellular changes. Thirty women had normal-appearing cervices and completely visualized transformation zones at colposcopy. Local and central pathologists concurred on a diagnosis of CIN in 2 of these 30 women. Both women had normal or benign cervical cytologic results; thus biopsy of colposcopically normal cervical tissue was the only evidence for CIN.
Association of HPV infection and CIN. The presence of any HPV infection according to the Hybrid Capture tube assay was significantly associated with CIN on the local pathologist's interpretation (P = .01), and high-risk HPV DNA was associated with CIN II or CIN III (P = .01). Quantitative measures of total HPV DNA were strongly associated with the presence of CIN (P = .005), and quantitative measures of DNA of high-risk HPV types were associated with the presence of CIN II or CIN III (P = .0006). There was no boundary value for quantitative total HPV DNA above which all women had CIN, nor was there a boundary value for high-risk HPV DNA and high-grade CIN. The dose-response relationship is illustrated by dividing subjects with HPV infection into 3 approximately equal groups according to level of total HPV DNA or high-risk HPV DNA (Table II) . Fifty-two percent of women in the group with the most total HPV DNA had CIN on biopsy, and 33% of women in the group with the most high-risk HPV DNA had high-grade CIN.
Screening characteristics. The receiver operating characteristic curve for quantitative measure of total HPV DNA as a marker for any CIN was similar to the receiver operating characteristic curve for Papanicolaou test result as a marker any CIN (Fig 1, A) . A level of ≥3 RLU/PC for total HPV DNA provided approximately the same sensitivity and somewhat lower specificity for CIN as the finding of atypical squamous cells of uncertain significance, atypical glandular cells of uncertain significance, or more se- 
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vere lesions on Papanicolaou test. Cutoff points of 10 RLU/PC and 100 RLU/PC for total HPV DNA provided nearly the same sensitivity and slightly lower specificity for CIN as cutoff points of low-grade and high-grade squamous intraepithelial lesions, respectively. The receiver operating characteristic curves for quantitative measures of high-risk HPV DNA or Papanicolaou tests as markers for CIN II and CIN III were also similar (Fig 1, B) . tures was considered as a positive screen result, the sensitivity for any CIN was higher than that of an abnormal Papanicolaou test result but the specificity was lower (Table  IIIA) . When either an epithelial cell abnormality or a positive result for either HPV probe mixture was considered as a positive screen result (parallel testing), the sensitivity improved slightly but with a further reduction in specificity. Selection of an appropriate cutoff point in quantitative HPV DNA testing further improved the screening characteristics. Similar results were obtained in analyzing high-risk HPV DNA levels and high-grade CIN (Table  IIIB) . The screening characteristics of Papanicolaou tests, of total and high-risk HPV DNA assays, and the combination of cytologic and DNA assays for CIN and highgrade CIN were nearly identical with the use of central cytopathologic results (data not shown).
Twelve-month follow-up. Local interpretations of specimens from repeated cervical biopsy and curettage 6 to 12 months after the initial visit were available for 49 of the 91 women eligible for observation without treatment. Follow-up biopsy revealed CIN in 2 of 8 women with CIN on initial biopsy (25%), in 2 of 14 with HPV or condyloma on initial biopsy (14%), in 6 of 24 with inflammation or other benign findings on initial biopsy (25%), and in 0 of 3 women with normal findings on initial biopsy. According to follow-up specimen interpretation by the local pathologists, the incidence of CIN among women without CIN at baseline was 20% in 1 year, including a single case of CIN II. The incidence of CIN according to central readings was 23%, and it was 10% for high-grade CIN.
Demographic, behavioral, clinical, and laboratory factors were tested for association with CIN at follow-up. Age at first sexual intercourse was significantly lower among women with incident CIN compared with those without CIN (median, 14 years vs 16 years; P = .02). Neither CD4 + lymphocyte counts at baseline or at follow-up nor changes in CD4 + lymphocyte counts were associated with development of CIN. Incident CIN was significantly associated with baseline total HPV DNA (median, 9.78 RLU/PC for incident CIN vs 1.84 RLU/PC; P = .03) and baseline high-risk HPV DNA (median, 6.10 RLU/PC for incident CIN vs 0.97 RLU/PC; P = .03). A cutoff point for baseline total HPV DNA of 1.90 RLU/PC was a better predictor of CIN on follow-up biopsy (Table IIIC) than of CIN at baseline (Table IIIA) and compared favorably with repeated cervical cytologic examination. Incident highgrade CIN was rare in our small cohort, so prediction rates for CIN II or CIN III according to high-risk HPV DNA levels were unstable.
Among 35 women without high-grade CIN on initial biopsy and without an epithelial call abnormality on initial cytologic examination, 33 local interpretations of Papanicolaou tests were available from the 6-month visit and 2 were available from the 12-month visit. Among 7 women with an epithelial cell abnormality on follow-up, 3 (43%) had CIN on biopsy, and among 28 women with no epithelial cell abnormality, 2 (7%) had CIN (P = .04). Papanicolaou tests within 6 to 12 months after initial screening had characteristics similar to baseline cytologic results, although point estimates of specificity and positive predictive value were higher for follow-up cytologic results (Tables IIIA and IIIC). Results according to central readings were nearly identical (data not shown). In our cohort of HIV-infected women, with a 27% prevalence of CIN and a 20% annual incidence of CIN, women with 2 negative Papanicolaou test results during a 6-to 12-month interval still had a 7% chance of having undiagnosed CIN.
Comment
We found that high levels of cervical HPV DNA were strongly associated with CIN and that cross-sectional screening characteristics of the quantitative HPV DNA assay were similar to those of cervical cytologic examination. Baseline quantitative HPV DNA measurement was predictive of incident CIN. We could not explore the potential of quantitative high-risk HPV DNA measures for predicting incident high-grade CIN, because we had few cases of CIN II or CIN III during the 1-year follow-up of our small cohort.
Our estimates of the sensitivity and specificity of cervical cytologic examination among HIV-infected women are slightly lower than published estimates in other populations 10 and are similar to other results from immunosuppressed HIV-infected women. 4, 11 The high prevalence of all grades of CIN consistently observed among such women leads to a low negative predictive value for Papanicolaou tests. Minor cytologic abnormalities are associated with a far higher rate of CIN than among HIVseronegative women. 12 We therefore believe that all epithelial cell abnormalities in immunocompromised HIV-infected women, including ASCUS (atypical squamous cells of undetermined significance), should be considered abnormal and an indication for colposcopy. Use of this broader criterion would improve the sensitivity and negative predictive value relative to squamous intraepithelial lesions alone (comparison not shown) but would still miss a sizable proportion of women with CIN and high-grade CIN.
We investigated the use of the first-generation Hybrid Capture tube assay for HPV DNA, a commercially available assay, as a screening tool. A dose-response relationship between the amount of high-risk HPV DNA detected by the Hybrid Capture tube assay and the frequency of high-grade CIN was previously documented among college women referred for colposcopy. 13 We confirmed dose-response relationships among HIV-infected women of total HPV DNA with CIN and of high-risk HPV DNA with CIN II or CIN III.
Quantitative Hybrid Capture tube results performed nearly as well as but no better than cervical cytologic examination. Combining Papanicolaou tests and the HPV DNA assay in parallel screening modestly improved sensitivity but reduced specificity, as expected. The 95% confidence intervals for the characteristics of the combined screening tests overlapped with those of cervical cytologic examination. The next generation of Hybrid Capture assays for HPV DNA detects 5 additional intermediate-risk HPV types and lower quantities of DNA. 7 Use of the microplate-based Hybrid Capture II method may further increase sensitivity for CIN but again sacrifice specificity, depending on the quantitative cutoffs selected. We were unable to assess the usefulness of the HPV assay among women with HIV and atypical squamous cells of uncertain significance because of our small sample. Larger studies performed in the general population suggest that concurrent detection of high-risk HPV DNA types among women with atypical squamous cells of undetermined significance can distinguish among women with and without high-grade CIN requiring colposcopy. 14 The US Public Health Service and the Infectious Disease Society of America recommend that a second Papanicolaou test be performed within 6 months of a normal initial Papanicolaou test result and that screening be repeated annually after 2 normal Papanicolaou test results. 15 In our cohort repeated Papanicolaou tests among women with no epithelial cell abnormality on initial Papanicolaou test (and no high-grade CIN on initial biopsy) had higher point estimates for specificity and likelihood ratio (for a positive test result) than the initial test, but otherwise the 2 tests performed similarly. Normal results of repeated cytologic examination after an initial normal Papanicolaou test result reduce the odds that biopsy will reveal CIN by a further 50% and may reduce the odds of high-grade CIN even further. Nevertheless, in light of the high incidence of CIN during the year after routine colposcopy and biopsy, we suggest that intensive screening should continue at least as long as HIV-infected women have some degree of immunosuppression.
Goldie et al 16 suggested that the Centers for Disease Control and Prevention and Infectious Diseases Society of America recommendations were appropriate according to cost-effectiveness analysis. In that study the annual incidence of CIN among HIV-infected women was estimated as 0.67 cases per 100 person years on the basis of small, often unpublished studies. In contrast, Ellerbrock et al 17 recently reported an annual incidence of 8.3 CIN cases per 100 person years among 328 HIV-infected women who underwent cytologic examination and colposcopy at baseline and every 6 months for a mean of 30 months. One third of the women had CD4 + lymphocyte counts >500 cells/mm 3 , and CIN incidence increased with decreasing CD4 + lymphocyte count. We observed a higher incidence of CIN in our smaller and more immunosuppressed cohort, and we recommend continued frequent cytologic screening of immunosuppressed women until data from additional long-term studies are available. Baseline levels of total and high-risk HPV DNA were statistically significantly higher for women with incident CIN. It is possible that baseline levels of high-risk HPV DNA could be used to discriminate women at risk for incident high-grade CIN who would most benefit from frequent follow-up screening. Too few cases of highgrade CIN occurred during follow-up for us to explore this possibility.
In our study and others 4 occasional cases of CIN have been missed by colposcopy without biopsy. Interpretive errors in colposcopy confer a greater risk of missing disease in high-prevalence populations, analogous to our discussion of cytologic results. Others have examined the contribution of sampling error, screening error, and interpretive error in cases in which cytologic results and biopsy results do not correlate. 18 We wish to emphasize the importance of correlating cytologic, colposcopic, and histologic findings in high-prevalence populations.
Strengths of our study include a well-characterized cohort of women with a range of immunosuppression seen in clinical care settings who were not selected because of previous abnormal cervical cytologic results and who represented a geographic and ethnographic cross-section of US HIV-infected women. Commercially available HPV DNA assays were run in batches, in a masked fashion, at the Digene HPV testing laboratory. All women underwent colposcopy and cervical biopsy with endocervical curettage, which eliminated bias in the ascertainment of disease. After reading by the local cytopathologists, all Papanicolaou tests and tissue specimens were read in a masked fashion by a central study cytopathologist. The primary analysis was performed with the local cytopathologists' interpretations, to mimic clinical practice, and the analysis was repeated with the central cytopathologists' interpretations with the same results. The principal weaknesses of this study are the small size of the cohort and the losses to follow-up. The 95% confidence bounds on screening characteristics were wide, and the power to detect significant associations between HPV DNA levels and CIN incidence and progression was low.
Our results reinforce the need for diligence in screening for cervical neoplasia among immunosuppressed HIV-infected women. The number of women with CIN and high-grade CIN missed by annual cytologic screening may be reduced by repeating the initial Papanicolaou test every 6 months among immunosuppressed women, the strategy that we favor. Use of colposcopy as part of the initial screen identifies more cases of CIN and allows assessment of vulvar disease, but frequent follow-up would still be necessary in light of the high incidence of CIN after colposcopy. Inclusion of an HPV DNA assay in screening improves sensitivity as well and may allow the selection of women who would benefit from more intensive follow-up. Results from other longitudinal studies of HIVinfected women will provide additional data on the incidence, natural history, and response of CIN to both local gynecologic treatment and antiretroviral therapy and will permit refinement of the current screening strategies.
